This is really what keeps me up at night: A therapy of this cost is going to have enormous implications for everyone. And by everyone, I literally mean you, too. There’s going to be some 60- and 70-year-olds on your plan. If they start getting this treatment, you will see your premiums will go up.

Dr. Joseph Ross, a pharmaceutical policy expert at Yale who sits on a committee that advises Medicare on some coverage decisions, commenting to The New York Times this week for its report, “Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense.”